Condition P02W

Weight maintenance after a GLP-1 receptor agonist containing run in

Participants randomized after a run in on a GLP-1 receptor agonist containing drug to continuation; withdrawal or another maintenance strategy. Tolerability and response enrichment criteria of the run in are recorded separately.

5 randomized trials; 8 fitted analyses across 12 outcomes.

All outcomes

Each outcome is analyzed per time window and estimand, with doses kept apart (each dose) and pooled (each medicine). Analyses with too few connected trials are shown as descriptive.

Serious adverse events

O25

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	2	3	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	2	3	Descriptive only

Discontinuation due to adverse events

O26

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only

Nausea

O27A

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	2	3	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately	2	3	Network meta-analysis

Vomiting

O27B

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	2	3	Network meta-analysis
longest follow-up	Recorded harms	Doses of a drug pooled	2	3	Network meta-analysis

Diarrhea

O27C

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	2	3	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately	2	3	Network meta-analysis

Constipation

O27D

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	2	3	Network meta-analysis
longest follow-up	Recorded harms	Doses of a drug pooled	2	3	Network meta-analysis

Discontinuation due to gastrointestinal adverse events

O27E

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only

Gallbladder and biliary disease

O28

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only

Acute pancreatitis

O29

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only

Suicidal ideation or behavior

O35A

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only

Death by suicide

O35B

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only

Acute kidney injury

O121

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only